Loading clinical trials...
Loading clinical trials...
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Conditions
Interventions
GZ/SAR402671
Locations
7
United States
Investigational Site Number 840002
Atlanta, Georgia, United States
Investigational Site Number 840003
Cincinnati, Ohio, United States
Investigational Site Number 840001
Fairfax, Virginia, United States
Investigational Site Number 250001
Garches, France
Investigational Site Number 616001
Warsaw, Poland
Investigational Site Number 643002
Moscow, Russia
Start Date
July 7, 2015
Primary Completion Date
November 20, 2018
Completion Date
November 20, 2018
Last Updated
March 23, 2021
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06226987
NCT06065852
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions